[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343171-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343171-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-and-immunological-implications-of-heterogeneous-cell-death-patterns-in-prostate-cancer","Prognostic and immunological implications of heterogeneous cell death patterns in prostate cancer","","Prostate cancer remains a major malignancy, with many patients developing biochemical recurrence after treatment. Programmed cell death (PCD) pathways influence tumor progression and may act as prognostic and therapeutic biomarkers. This study analyzes 19 PCD modes using bulk and single-cell transcriptomic, genomic, and clinical data across multiple cohorts to build, evaluate, and validate a PCD-based prognostic index for recurrence risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-and-immunological-implications-of-heterogeneous-cell-death-patterns-in-prostate-cancer/343171/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-and-immunological-implications-of-heterogeneous-cell-death-patterns-in-prostate-cancer/343171.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main goal in prostate cancer?","Question",{"text":63,"@type":64},"To develop a prognostic signature for biochemical recurrence in prostate cancer using genes related to programmed cell death.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the prognostic model developed and validated?",{"text":68,"@type":64},"The analysis covered 19 programmed cell death modes using data from multiple cohorts, then constructed and validated a Programmed Cell Death Index (PCDI) in independent datasets.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical and biological associations were found for the PCDI?",{"text":72,"@type":64},"Higher PCDI values related to increased biochemical recurrence risk, higher T and N stages, reduced drug sensitivity, and immune-related differences including links to immune checkpoint genes and tumor microenvironment components.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343171,1790445449,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Wang et al. Cancer Cell International (2024) 24:297 Cancer Cell International  \n[https://doi.org/10.1186/s12935-024-03462-7](https://doi.org/10.1186/s12935-024-03462-7)  \nRESEARCH Open Access  \nPrognostic and immunological implications of heterogeneous cell death patterns in prostate cancer  \nMing Wang 1†, Bangshun Dai 1†, Qiushi Liu 1† and Xiansheng Zhang 1*  \nAbstract  \nBackground Prostate cancer is one of the most common cancers in men with a significant proportion of patients developing biochemical recurrence (BCR) after treatment. Programmed cell death (PCD) mechanisms are known to play critical roles in tumor progression and can potentially serve as prognostic and therapeutic biomarkers in PCa. This study aimed to develop a prognostic signature for BCR in PCa using PCD-related genes.  \nMaterials and methods We conducted an analysis of 19 different modes of PCD to develop a comprehensive model. Bulk transcriptomic, single-cell transcriptomic, genomic, and clinical data were collected from multiple cohorts, including TCGA-PRAD, GSE58812, METABRIC, GSE21653, and GSE193337 . We analyzed the expression and mutations of the 19 PCD modes and constructed, evaluated, and validated the model.  \nResults Ten PCD modes were found to be associated with BCR in PCa, with specific PCD patterns exhibited by various cell components within the tumor microenvironment. Through Lasso Cox regression analysis, we established a Programmed Cell Death Index (PCDI) utilizing an 11-gene signature. High PCDI values were validated in five independent datasets and were found to be associated with an increased risk of BCR in PCa patients. Notably, older age and advanced T and N staging were associated with higher PCDI values. By combining PCDI with T staging, we constructed a nomogram with enhanced predictive performance. Additionally, high PCDI values were significantly correlated with decreased drug sensitivity, including drugs such as Docetaxel and Methotrexate. Patients with lower PCDI values demonstrated higher immunophenoscores (IPS), suggesting a potentially higher response rate to immune therapy. Furthermore, PCDI was associated with immune checkpoint genes and key components of the tumor microenvironment, including macrophages, T cells, and NK cells. Finally, clinical specimens validated the differential expression of PCDI-related PCDRGs at both the gene and protein levels.  \nConclusion In conclusion, we developed a novel PCD-based prognostic feature that successfully predicted BCR in PCa patients and provided insights into drug sensitivity and potential response to immune therapy. These findings have significant clinical implications for the treatment of PCa.  \n†Ming Wang, Bangshun Dai and Qiushi Liu contributed equally to this work.  \n*Correspondence: Xiansheng Zhang [xiansheng-zhang@163.com](xiansheng-zhang@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it.The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icens","cbCaivDU0saIRTf8","https://ap.wps.com/l/cbCaivDU0saIRTf8","pdf",10926392,17,"English","# Abstract\n# Background\n# Materials and methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the study’s main goal in prostate cancer?\",\"answer\":\"To develop a prognostic signature for biochemical recurrence in prostate cancer using genes related to programmed cell death.\"},{\"question\":\"How was the prognostic model developed and validated?\",\"answer\":\"The analysis covered 19 programmed cell death modes using data from multiple cohorts, then constructed and validated a Programmed Cell Death Index (PCDI) in independent datasets.\"},{\"question\":\"What clinical and biological associations were found for the PCDI?\",\"answer\":\"Higher PCDI values related to increased biochemical recurrence risk, higher T and N stages, reduced drug sensitivity, and immune-related differences including links to immune checkpoint genes and tumor microenvironment components.\"}]","Prognostic and immunological implications of heterogeneous cell death patterns in prostate cancer | PDF",1790050166,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97c9e6cb2b6e0478402be6f6ef6deb52.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/515a1b40e5012867b91e08061a5f75e6.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87cbe6aba6f739b8d54847e1abaa475a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b7731922817357cfdaecfafff9a3686.webp",980,1306]